Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
Conference Call and Webcast Information
- Date:
Wednesday, August 12, 2026 at4:30 PM ET /1:30 PM PT Participant Dial -in (North America ): 1-800-836-8184Participant Dial -in (International): 1-646-357-8785- Conference ID: 50873
- Webcast Access: Click here
The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.
A replay of the webcast will be available on the Talphera website for 90 days after the event.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-report-second-quarter-2026-financial-results-on-wednesday-august-12-2026-302844071.html
SOURCE Talphera, Inc.
Investor Contacts, Talphera, Raffi Asadorian, CFO, 650-216-3500, investors@talphera.com; LifeSci Advisors, Kevin Gardner, 617-283-2856, kgardner@lifesciadvisors.com